Fig. 1From: Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indicationsThe survival curves of HCC patients with and without tumor occupation ≥50% volume of live (TO ≥50%). TO ≥50% had significantly negative impact on the PFS (A) and OS (B) (both p value < 0.001)Back to article page